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Abstract Cell division relies on coordinated regulation of the
cell cycle. A process including a well-defined series of strictly
regulated molecular mechanisms involving cyclin-dependent
kinases, retinoblastoma protein, and polo-like kinases. Dys-
functions in cell cycle regulation are associated with disease
such as cancer, diabetes, and neurodegeneration. Compart-
mentalization of cellular signaling is a common strategy used
to ensure the accuracy and efficiency of cellular responses.
Compartmentalization of intracellular signaling is maintained
by scaffolding proteins, such as A-kinase anchoring proteins
(AKAPs). AKAPs are characterized by their ability to anchor
the regulatory subunits of protein kinase A (PKA), and there-
by achieve guidance to different cellular locations via various
targeting domains. Next to PKA, AKAPs also associate with
several other signaling elements including receptors, ion chan-
nels, protein kinases, phosphatases, small GTPases, and phos-
phodiesterases. Taking the amount of possible AKAP signal-
ing complexes and their diverse localization into account, it is
rational to believe that such AKAP-based complexes regulate
several critical cellular events of the cell cycle. In fact, several
AKAPs are assigned as tumor suppressors due to their vital
roles in cell cycle regulation. Here, we first briefly discuss the
most important players of cell cycle progression. After that,
we will review our recent knowledge of AKAPs linked to the
regulation and progression of the cell cycle, with special focus
on AKAP12, AKAP8, and Ezrin. At last, we will discuss this
specific AKAP subset in relation to diseases with focus on a
diverse subset of cancer.
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Introduction
The growth of organisms is driven by cell division which
relies on coordinated regulation of phases in cell cycle [4].
When the cell is quiescent, it remains in the G1 phase; how-
ever, on initiation of cell division, it progresses into the S
phase, during which DNA replication occurs, followed by a
separation of sister chromatids during the M phase, which in
turn is again separated in the pro-, meta-, ana-, and telophase,
followed by cytokinesis where the actual cell division occurs.
A series of strictly regulated molecular mechanisms are re-
quired to maintain the progression of the cell cycle including
cyclin-dependent kinases (CDKs), retinoblastoma protein
(Rb), and polo-like kinases (Plks) [10, 24, 117]. In accor-
dance, several diseases have been found to directly or indi-
rectly relate to a defective regulation of the cell cycle, such as
cancer, diabetes, and neurodegeneration [93, 115].
Importantly, over the past years, it is accepted that compart-
mentalization of cellular signaling is a common strategy used
to ensure the accuracy and efficiency of cellular responses
[67]. Cellular compartmentalization of proteins involved in
signal transduction is maintained by scaffolding proteins, such
as A-kinase anchoring proteins (AKAPs), which are able to
orientate a diverse subset of signaling effectors, such as pro-
tein kinase A (PKA), extracellular-signal-regulated kinase
(ERK), and cyclins, towards selected substrates in specific
cellular microdomains [80, 91, 109]. AKAPs are characterized
by their ability to anchor the regulatory subunits of PKAvia a
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conserved short α helical structure, and thereby achieve guid-
ance to different cellular locations via various targeting do-
mains. PKA is a cAMP-dependent serine/threonine kinase
and a very important player in many different cellular path-
ways. The involvement of PKA in the cell cycle progression is
diversely regulated in different cell types. In Xenopus embry-
onic cells, PKA activity is low during the M phase but in-
creases during M/G1 transition, [36, 37], whereas in the hu-
man cancer cell line HeLa, PKA activity is increased during
the M phase [104]. PKA negatively regulates the cell cycle
progression upon activation of the small GTPase Rap1 and
subsequent sequestration of Ras/MEK/ERk [22, 89]. Inhibi-
tion of the cell cycle progression by PKA can also be achieved
upon upregulation of the CDK inhibitor p27Kip1 [46].
Next to PKA, AKAPs also associate with several other
signaling elements including receptors, ion channels, protein
kinases, phosphatases, small GTPases, and phosphodiester-
ases [23, 80, 91]. Until now, over 50 members of the AKAP
family have been identified, and each AKAP can form a
unique signaling complex in different microdomains in the
cells [29, 80, 91, 103]. With the large variety of AKAP sig-
naling complexes at many different locations inside the cell, it
is feasible that such AKAP-based complexes regulate several
critical cellular events of the cell cycle. In fact, several AKAPs
are assigned as tumor suppressors due to their vital roles in cell
cycle regulation.
Although the function of AKAP-PKA interactions in the
cell cycle is not well understood, the role of some AKAPs
being unveiled and will be described in this review. Here,
we first briefly discuss the most important players of cell cycle
progression. After that, we will review our recent knowledge
of AKAPs linked to the regulation and progression of the cell
cycle, with special focus on AKAP12, AKAP8, and Ezrin. In
the final section, we will discuss more about AKAP12 and
Ezrin in relation to disease.
Players of cell cycle regulation
The cell cycle is controlled by the activity of CDKs, which in
turn are controlled by cyclins such as cyclin D/E [112]. Ex-
posing cells to growth factors will elevate the amount of
cyclins e.g., cyclin D1 in the cell through the Ras/Raf/MEK/
ERK signaling cascade, [16, 76, 82], which can combine with
pre-existing CDKs to activate or inactivate target proteins,
such as Rb, to orchestrate the entry into the different phases
of the cell cycle [74]. The activity of cyclin-CDK complexes
is tightly controlled, as check points, to fine-tune the cell cy-
cle. For example, Plk1 activates cyclin B-CDK1 complex,
during the prophase to initiate the G2/M transition [100,
101]. In addition, also the degradation of cyclins by
ubiquitination allows cells to enter a next phase of the cell
cycle. For example, human enhancer of invasion 10 (HEI10)
functions as an E3 ubiquitin ligase to inhibit the progression
into the M phase by decreasing the levels of cyclin B [99]. In
addition, the M phase is regulated by a series of complexes or
enzymes that control chromosome segregation and condensa-
tion (e.g., condensin, histone H3, and Aurora B kinase) [42,
58, 108]. In Fig. 1, the interactions between AKAPs and sev-
eral key players in cell cycle regulation are summarized.
AKAP12
AKAP12, originally called Gravin or AKAP250, was first
recognized as an autoantigen in serum frommyasthenia gravis
patients [35]. Later, AKAP12 was found orthologous to a
rodent protein, the Src-suppressed C Kinase Substrate
(SSeCKS) [62]. Since its discovery as an AKAP [73],
AKAP12 is probably one of the most studied AKAPs in the
cell cycle regulation [34]. Several reports indicate that
AKAP12 generally regulates the cell cycle upon engagement
of distinct cell cycle phases: (1) acting as a negative regulator
during inappropriate cell cycle progression; (2) helping to fa-
cilitate mitosis and cytokinesis [1, 73].
AKAP12 as a negative regulator of the G1/S transition
AKAP12 regulates the cell cycle by reducing cyclin D1 ex-
pression presumably mediated via inhibition of ERK [16, 82,
97, 105]. For example, Lin et al. reported in NIH 3T3 cells that
induction of AKAP12 expression by tetracycline suppressed
ERK2-dependent cyclin D1 expression and Rb phosphoryla-
tion, effects that coincided with a G1 arrest [60]. Conversely,
knockdown of AKAP12 in a C6 rat glioma cells reversed
dexamethasone-induced growth arrest, which was associated
with elevated phosphorylation of ERK1/2 and expression of
cyclin D1 [63]. Regulation of ERK might be mediated by
controlling Src-focal adhesion kinase (FAK) complexes.
AKAP12 sequesters Src through direct binding [61, 95],
thereby disengaging Src-FAK complexes away from ERK
[1, 34]. Besides affecting the expression of cyclin D1,
AKAP12 also sequesters cyclin D1, and thereby inhibits its
nuclear translocation. In AKAP12-overexpressing NIH 3T3
cells, the majority of cyclin D1 co-localized with AKAP12
in the cytoplasm, and nuclear cyclin D1 was reduced by about
70 % compared to controls [60]. In agreement, Burnworth
et al. showed that cell-cell contact-induced AKAP12 expres-
sion sequesters cyclin D1 and prevents its nuclear transloca-
tion, resulting in growth arrest of glomerular parietal epithelial
cells [12]. AKAP12-mediated cyclin D1 sequestration is
inhibited by protein kinase C (PKC) phosphorylation of
AKAP12 [59] and short-term activation of PKC induced nu-
clear translocation of cyclin D1 even under AKAP12-
overexpression (Fig. 1) [60].
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AKAP12 is important for the completion of cytokinesis
AKAP12 regulates cell cycle progression by facilitating the
cytokinesis. In HeLa cells, Choi et al. found that knockdown
of AKAP12 resulted in a profound rounding up of the cell
morphology and multi-nucleated cells at later stages of cyto-
kinesis compared to controls, leaving the anaphase and telo-
phase of the cell cycle unchanged [19]. Similarly, AKAP12-
deficient mouse embryonic fibroblasts proliferated faster com-
pared to wild-type cells in early passages, but lost all prolifer-
ative capacity during later passages and showed significant
Rb-dependent cell senescence and multi-nucleation [2].
AKAP12 is known to bind to PKC, thereby decreasing PKCα
and δ activity [2, 40]. PKCα can lead to cell senescence by
activation of p16INK4a/Rb [96], while PKCδ causes the
downregulation of Lats1/Warts, a mitotic exit network kinase
required for completion of cytokinesis [45, 111]. In addition,
in HEK293 cells, AKAP12 was found to co-localize with
actin near the actin-myosin contractile rings known to be im-
portant to complete cytokinesis (Fig. 1) [19]. Reports have
shown that PKC completes cytokinesis upon contraction of
the actin-myosin ring [9, 87]. AKAP12 might be involved in
the regulation of cytokinesis by controlling the contraction of
actin-myosin rings by scaffolding PKC and actin.
Recently, AKAP12 was also found to form a complex with
a mitotic kinase Plk1 (Fig. 1) [13], known to activate the
cyclin B-CDK1 complex during G2/M phase transition
[100, 101]. Interestingly, phosphorylation of AKAP12 by
Fig. 1 A-kinase anchoring proteins regulate the cell cycle by spatial and
temporal interaction with several key players. With the initiation of the
G1 phase, cyclin-CDK signaling is crucially mediated by several AKAPs,
most notably AKAP5, AKAP8, and AKAP12. AKAPs can mediate this
by controlling either the expression, nuclear translocation, or activity of
the cyclins and/or CDKs. During the S phase, only the interaction of
AKAP8 with the DNA replication complex is known. Throughout the
different stages of the M phase AKAPs, again mainly AKAP8 and
AKAP12, play a role in coordinating the initiation and finalizing of dif-
ferent stages from chromatin condensation until the cytokinesis that is at
the very end. AKAP12 regulates the cell cycle by (a) acting as a negative
regulator during inappropriate cell cycle progression and nb) supporting
mitosis and cytokinesis. As illustrated, AKAP12 decreases cyclin D ex-
pression via ERK. AKAP12 binds also to cyclin D1 to prevent its nuclear
translocation. On the other hand, AKAP12 supports cytokinesis comple-
tion by controlling actin-myosin rings via scaffolding of PKC and actin.
In addition, AKAP12 forms a complex with the mitotic kinase Plk1,
known to activate the cyclin B-CDK1 complex during G2/M phase tran-
sition. As the only identified AKAP within nucleus, AKAP8 functions as
a multivalent platform to anchoring different signaling elements during
cell cycle regulation. AKAP8 helps to recruit MCM2 to DNA and pro-
motes thereby its replication during S phase. In the presence of growth
factors, AKAP8 localizes to ERK-induced RSK1 in the nucleus to sub-
sequently induce cell proliferation. Moreover, AKAP8 supports the de-
livery of cyclin D/E to CDKs and thereby facilitates cell cycle progres-
sion. During the M phase, AKAP8 recruits HDAC3 to the vicinity of
chromatin and thereby initiates chromatin condensation. Subsequently,
AKAP8 localizes the condensin complex to chromatin and initiates there-
by chromatin condensation. Together with Merlin, Ezrin helps centro-
some positioning and thereby guides mitotic spindle orientation during
cell division. AKAP8 also decreases cyclin A expression by acting as a
transcriptional repressor, and thereby reduces cell proliferation. AKAP5
modulates cell proliferation by affecting the expression of a specific
CDK2 inhibitor p27kip1. Together with KSR-1, AKAP13 forms a scaf-
folding core, thereby allowing tuning of ERK signaling. Merlin controls
cyclin B1 levels by HEI10 localization. Merlin seems also to repress
cyclin D1 expression through its interaction with another tumor suppres-
sor, PICT-1. For further details, abbreviations and references, see text
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CDK1 was required for the binding of Plk1 to AKAP12
(Fig. 1). Taking together, AKAP12may amplify the formation
of cyclin B-CDK1 complexes due to its ability to function as a
scaffolding protein for Plk1. As support, disruption of
AKAP12-Plk1 using a Plk1-binding deficient AKAP12 mu-
tant decreased cell proliferation [14]. Conclusively, AKAP12
may play an important role in cell cycle regulation and may
thus represent a potential target for the treatment of cancer and
other proliferation-associated diseases.
AKAP8
AKAP8, also known as AKAP95, is an AKAP that has been
identified to reside in the nucleus, which leaves no surprise
that AKAP8 is involved in DNA replication and the expres-
sion levels of several proteins that regulate the cell cycle
(Fig. 1) [91].
AKAP8 in interphase
As outlined below, various studies suggest AKAP8 regulates
the cell cycle through its interaction with different proteins
during interphase, such as minichromosomemaintenance pro-
tein 2 (MCM2), ribosomal S6 kinase 1 (RSK1), and cyclin D/
E (Fig. 1). Using a yeast two-hybrid screening, one of the
AKAP8-binding proteins identified in HeLa cells was
MCM2, a component of the DNA pre-replication complex,
which is in charge of DNA replication [28, 56]. Disruption
of the AKAP8-MCM2 interaction by GST-AKAP8 peptides
decreased or even abolished DNA replication. In S phase nu-
clei, depletion of chromatin-associated AKAP8 by partially
removed MCM2 and inhibited the initiation and elongation
phases of DNA replication [28], suggesting that AKAP8 plays
a central role in controlling MCM2 function.
Activation of RSK1 by ERK1/2 leads to its subsequent
translocation to the nucleus, phosphorylation of downstream
substrates, and growth factor-induced proliferation [6]. In
HeLa cells, Gao et al. discovered that an AKAP-PKA inter-
action inhibitor, stearated Ht31, reduced epidermal growth
factor-induced RSK1 nuclear translocation [32]. Taken to-
gether, these data indicate that AKAPs are involved in the
nuclear retention of RSK1. Combining immuno-
precipitation and liquid chromatography-mass spectrometer
analyses, AKAP8 was indeed identified as the AKAP respon-
sible for this nuclear retention of RSK1. Supportively, silenc-
ing of AKAP8 decreased nuclear RSK1 and increased cyto-
solic RSK1 (Fig. 1) [32].
In Chinese hamster ovary cells, AKAP8 could co-
immunoprecipitate with cyclin D [8] and cyclin E1 [7]
(Fig. 1). Interestingly, cyclin D/E were found to combine with
either AKAP8 or CDK4, indicating a competition for cyclin
binding [7]. Interactions between AKAP8 and cyclin D/E
were impaired upon overexpression of CDK4 in the cells [7,
8], suggesting that AKAP8 may help to deliver cyclin D/E to
CDK4 to facilitate cell cycle progression. As cyclins require to
be combined with a distinct subset of CDKs to exert a regu-
latory function on the cell cycle [112], these findings provide
another mechanism for AKAP8 to regulate the cell cycle.
AKAP8 is important for chromatin condensation
It is reported that AKAP8 helps to regulate chromatin conden-
sation by interacting with the DNA and other proteins during
the mitotic phase. In HeLa cells, Steen et al. found, byWestern
blot analysis of the nuclear matrix and chromatin fractions
prepared at different phases of the cell cycle, that AKAP8
redistributed from the nuclear matrix to the chromatin upon
mitotic nuclear disassembly [94]. Meanwhile, AKAP8 was
found to directly interact with a human condensin complex
component, Eg7, and thereby to support its recruitment to
chromatin (Fig. 1) [21, 94]. The data suggest that AKAP8
regulates the M phase by localizing the condensin complex
to chromatin via its direct interaction with Eg7 during chro-
matin condensation.
Chromatin condensation is initiated by the phosphorylation
of histone H3 serine 10 by Aurora B kinase [42, 108]. This
phosphorylation is regulated by AKAP8 during chromatin
condensation. When cells enter the M phase, AKAP8 was
found to recruit histone deacetylase 3 (HDAC3) to the vicinity
of chromatin. The de-acetylation of histone H3 by HDAC3
resulted in a hypo-acetylated tail, which became a preferred
substrate for Aurora B kinase, allowing phosphorylation of
histone H3 at serine 10 [58]. In agreement, depletion of either
AKAP8 or HDAC3 induced G2/M arrest and substantially
increased cells with incomplete chromosomal condensation,
defects in chromosome segregation, and tri- or multipolar mi-
totic spindles [58].
Although PKA has been implicated as a negative regulator
for proliferation in several cell types such as airway smooth
muscle cells, vascular smooth muscle cells, NIH 3T3 cells,
and adipocytes [11, 15, 44, 88], other studies found that
PKA activity relatively increased during the M phase [36,
90]. Collas et al. found that Ht31, anti-AKAP8 antibodies,
the PKA inhibitors PKI or Rp-8-Br-cAMPS induced prema-
ture chromosome de-condensation [21], suggesting that
AKAP8-anchored PKA activity is essentially required for
condensed chromatin maintenance during the M phase. Fur-
ther studies indicated that PKA-AKAP8 anchoring requires
phosphorylation of PKA regulatory subunit IIα at threonine
54, as a PKA regulatory subunit IIα T54E mutant impaired in
phosphorylation, inhibited interaction between PKA and
chromatin-associated AKAP8 during the M phase [54]. The
cyclin B-CDK1 complex seems to be involved in this process,
as it had been found to phosphorylate at threonine 54 of PKA
RIIα during the M phase (Fig. 1) [50].
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Ezrin
Identified as an AKAP [25], Ezrin is a member of the Ezrin,
Radixin, and Moesin protein family, this family crosslinks the
membrane with its underlying actin cytoskeleton and helps to
regulate a diverse subset of signaling routes [30]. Although
many studies have related Ezrin with cancer metastasis and
invasion [53, 64, 69, 83], data also suggested that Ezrin may
play a role in cancer by regulating the cell cycle (Fig. 1) [18,
41, 51, 85, 86].
Ezrin was found to direct mitotic spindle orientation during
cell division [41]. Hebert et al. showed that Ezrin concentrated
at certain areas of the plasma membrane to form a cap-like
structure to help centrosome positioning, starting during G1
and reaching a peak by the S phase [41]. Interestingly, Ezrin
acts in concert with the closely related neurofibromatosis type
II (NF2) tumor suppressor Merlin to exert this function [41],
which was also identified as an AKAP (see below) (Fig. 1)
[39]. In cells expressing Merlin short hairpin RNA, cortical
Ezrin fails to form a cap-like structure, resulting in aberrantly
oriented spindles and polarization [41].
Besides functioning as a cytoskeletal protein and cortical
cue to direct mitotic spindle orientation, Ezrin seems to par-
ticipate also in cell cycle regulation by acting as a transcrip-
tional repressor. In endothelial cells, TNF-α induced a down-
regulation of cyclin A and decreased cell proliferation, which
seemed to be mediated by the nuclear recruitment of an 84-
kDa protein, that bound specifically to the cell cycle genes
homology region in the cyclin A promoter [52], which was
later identified as Ezrin [51]. Conversely, endothelial cells
transfected with dominant-negative Ezrin largely attenuated
TNF-α-induced downregulation of cyclin A promoter activity
and inhibition of proliferation. In a mouse hind limb ischemia
model, transplantation of dominant-negative Ezrin-transfected
endothelial cells improved blood flow recovery by increased
endothelial cell proliferation [51]. It is known that cytoskeletal
organization of Ezrin involves the Rho family of GTPases
[110]. Interestingly, the same study also found that the
TNF-α-induced Ezrin expression needed activation of RhoA
kinase [51]. Supportively, similar effects of Ezrin were also
discovered in another system, where fibroblast growth factor
induced Ezrin expression resulted in growth arrest in the G1
phase in rat chondrosarcoma cells [85].
In cancer cells however, Ezrin seems to act differently as it
plays a critical role during tumor progression by positively
regulating the cell cycle progression. In tongue squamous cell
carcinoma (SCC), high Ezrin expression correlated with an
increased Ki-67 index, a marker for tumor proliferation and
aggressiveness, although no obvious connection between the
expression level of Ezrin and the tumor stage was observed in
this study [86]. Furthermore, Ezrin was found to be involved
in cancer proliferation by affecting cell cycle distribution, as
silencing of Ezrin decreased the S and G2/M fractions and the
growth rate in human tongue SCC cell line HSC-3 [86]. Sim-
ilarly, in human lung cancer cell line 95D, Ezrin short hairpin
RNA arrested the cells in G0/G1 phases, which lead to the




AKAP5, also known as AKAP79, has been reported to reduce
cell proliferation by increasing the expression of p27kip1, a
specific CDK2 inhibitor, in a PKA dependent way (Fig. 1)
[46]. In line with this function, AKAP has been found in the
nuclear fraction [114]. In rat aortic smooth muscle cells,
Indolfi et al. found that overexpression of AKAP5 resulted
in high cAMP-dependent signaling, a process most likely re-
lying on the association of membrane-bound AKAP5 with
PKA, as the cAMP signaling was diminished by co-
expression of the PKA inhibitor PKI or a derivative of
AKAP5 without the membrane-anchoring domain. Enhanced
transcriptional activity of the cAMP-dependent CRE
promotor by AKAP5 was correlated with a high p27kip1 ex-
pression and low DNA synthesis level [46]. Supportively, in a
rat vascular injury model, site-specific gene transfection of
AKAP5 after balloon injury significantly increased the
p27kip1 level and inhibited neo-intimal hyperplasia [46].
AKAP13
Through the Raf/MEK/ERK cascade, the ERK pathway trans-
duces signals from growth factor-stimulated membrane recep-
tors to growth factor-responsive targets in the cytosol and
nucleus [81, 106]. It is already known that kinase suppressor
of Ras (KSR) acts as a scaffolding protein to modulate the
ERK signaling network (Fig. 1) [98]. Another study indicated
that besides KSR, AKAP13, also known as AKAP-Lbc, is
also involved in this signaling complex (Fig. 1) [92]. Using
HEK293 cells and NIH 3T3 fibroblasts, Smith et al. elucidated
a molecular model, in which AKAP13 and KSR form a scaf-
folding core to localize Raf in the vicinity of MEK, allowing a
signaling cascade from Raf, through MEK, to ERK1/2 [92].
The growth factor induced Raf/MEK/ERK cascade happens
during the G1/S transition [27, 68], pointing towards
AKAP13 playing a role during this transition. More impor-
tantly, this molecular model seems to suggest a reasonable
explanation for the positive effects of PKA on the ERK cas-
cade and cell proliferation [26], as the function of this signal-
ing complex was depended on the phosphorylation of Serine
838 on KSR by an AKAP13 anchored PKA (Fig. 1) [92].
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Merlin
As mentioned previously, Merlin is an AKAP that anchors
different signaling proteins to the actin cytoskeleton and in-
volves in cell signaling during cell proliferation [39]. Because
the mutation of human Merlin gene is known to cause NF2,
Merlin is also called neurofibromin 2 or schwannomin [84,
102]. As with Ezrin, it was found that cellular localization of
Merlin was dependent on the cell cycle [72]. Merlin was
found accumulated around the nucleus at the G2/M transition,
but localized tomitotic spindles and the contractile ring during
the M phase, and later more, Merlin was found underneath the
cortical membrane during the G1/S phases [72]. PKA phos-
phorylation coordinates a lot of Merlin’s functions as PKA
phosphorylation of Merlin at serine 10 is required for its in-
teraction with the actin cytoskeleton [55]. In addition, PKA
phosphorylation of Merlin at serine 518 causes a
heterodimerization with Ezrin [5], directing mitotic spindle
orientation during cell division [41]. The growth inhibition
effects of Merlin are linked to its regulation of cyclin B or
D1 (Fig. 1). In a rat schwannoma cell line, Grönholm et al.
found that Merlin expression is necessary for the subcellular
localization of HEI10 [38], a protein controlling the levels of
cyclin B1 by acting as a divergent class of E3 ubiquitin ligase
(Fig. 1) [99]. In addition, Merlin was suggested to repress
cyclin D1 expression through its interaction with another tu-
mor suppressor, protein interacting with carboxyl terminus 1
(PICT-1) in glioblastoma cells [17].
Relation to diseases
In the next section, we highlight some aspects of AKAP12,
Ezrin, and Merlin in a disease-related context. We summa-
rized the involvement of AKAPs in various diseases in
Table 1. AKAP12 gene is mapped to 6q24-25.2, which is a
hotspot for gene deletions during cancer progression [33, 34].
Downregulation of AKAP12 expression has been reported to
cause abnormal cell cycle regulation, leading to pulmonary ad-
enocarcinoma [107], prostatic hyperplasia [3], myelodysplastic
syndrome [77], and gastric carcinoma [20]. Data indicate that
gene silencing of the AKAP12 promoter through CpG island
hypermethylation is responsible for the downregulation of
AKAP12 in esophageal neoplastic progression [48], colon can-
cer [70], and gastric carcinoma [20], suggesting that hyperme-
thylation of the AKAP12 promoter may represent a potential
indication for the early detection of a distinct subset of diseases.
On the other hand, restoration of AKAP12 expression might be
beneficial in future treatment of cancer. Indeed, re-expression of
AKAP12 in gastric cancer cells restored cell growth by inducing
apoptosis [20]. Similarly, re-expression of AKAP12 suppressed
the ability of v-Src to induce cell growth and induced cell arrest
in an AKAP12 deficient cell line [61].
Unlike AKAP12, Ezrin expression and increased malig-
nancy seem to correlate in various human cancers, including
uterine cervical cancer [53], uveal malignant melanoma [65],
tongue SCC [86], hepatocellular carcinoma [49], brain astro-
cytoma [66], and atypical endometrial hyperplasia and uterine
endometrioid adenocarcinoma [75]. This suggests that Ezrin
Table 1 AKAPs and diseases
AKAPs Diseases References
AKAP12 Pulmonary adenocarcinoma [89]
Prostatic hyperplasia [3]
Myelodysplastic syndrome [64]
Esophageal neoplastic progression [38]
Colorectal cancer [58]
Gastric carcinoma [19]
Ezrin Uterine cervical cancer [43]
Uveal malignant melanoma [54]
Tongue squamous cell carcinoma [72]
Hepatocellular carcinoma [39]
Brain astrocytoma [55]
Atypical endometrial hyperplasia [62]
Uterine endometrioid adenocarcinoma [63]
Colorectal cancer [46]
Lung cancer [17]




For further details, see text
Fig. 2 Balance between a distinct subset of AKAPs important for disease
development. Expression of AKAP12 is decreased in various cancers and
COPD. In cancers, Ezrin switched from an anti-proliferative to a pro-
proliferative function. Cigarette smoke induced reduction of AKAP12
and elevation of Ezrin in airway smooth muscle might represent a com-
mon link between cancer and CODP. For further details and references,
see text
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expression could be a potential prognostic marker for these
diseases. In accordance, Ezrin knockdown by silencing RNA
decreased cell proliferation and survival rate in tongue SCC
cell line [86], human lung cancer cell lines [18], and colorectal
cancer cell lines [57]. Moreover, inhibition of Ezrin expres-
sion seem to reduce the chemotherapy resistance of human
lung cancer cells [18], suggesting a potential AKAP-related
strategy for this disease. Notably, Ezrin phosphorylation is
necessary for cancer cell proliferation. There is an increased
Ezrin phosphorylation at threonine 567 in liver metastasis
compared to the primary tumor. Interestingly, overexpression
of T567D Ezrin, a phospho-mimicking Ezrin mutant, promot-
ed the cancer cell proliferation [57, 116], while an over-
expression of wild-type Ezrin showed inhibitory effects
on cell proliferation [116].
The most studied disease that relates to Merlin is NF2, as it
is caused by mutations of the Merlin gene [84, 102]. Later
studies suggested that the mechanism behind its tumor sup-
pressor properties may also applies to other type of cancers
[71]. The tumor suppression mechanism of Merlin is mainly
associated with contact-mediated growth inhibition. At high
cell density, Merlin was found hypo-phosphorylated and its
growth-inhibitory activity was depended on interaction with
the cytoplasmic tail of CD44 [71]. In addition, Merlin is also
suggested to prevent centrosome amplification during tumor-
igenesis, as loss of Merlin fails to restrict Ezrin, leading to
incorrect centrosome position and multipolar spindle forma-
tion in Merlin-deficient Caco2 cells, BT-549 mammary tumor
cells and U2OS osteosarcoma cells [41]. For a comprehensive
understanding of the role of Merlin in tumors, the authors
recommend the latest review [78].
Conclusion
In conclusion, there are several indications that AKAPs can
regulate the cell cycle through either participating in signaling
pathway by themselves or functioning as the scaffolding pro-
teins that anchor and coordinate different signaling elements
(Fig. 1).
This review has focused only on a fewAKAPs, which have
been shown to link cell cycle alterations and disease (Table 1).
It is tempting to speculate that their balance could play an
important role in other diseases through a yet to be defined
mechanism. In this context, it is worthwhile to mention that
we have shown recently that cigarette smoke, a major cause
not only for lung cancer but also for chronic obstructive pul-
monary disease (COPD), provoked a decrease of AKAP12
and an increase of Ezrin expression in airway smooth muscle
[79]. Although both AKAP12 and Ezrin seem to inhibit pro-
liferation, as outlined in detail above Ezrin, seems to change
its function in cancer. Thus, it would be interesting to study if
Ezrin alters its function also in COPD. Taken together with
what we have discussed above, it seems that understanding
the balance of these AKAPs could be important to unravel
basic mechanisms underlying a variety of diseases (Fig. 2).
Several issues regarding to AKAPs in cell cycle regulation
need to drawmore attention. First, all AKAPs can bind to PKA,
but the role of PKA in AKAP-mediated cell cycle regulation is
still unclear. Second, some AKAPs were reported to interact
with the same signaling partners (e.g., cyclin B), what could
the mechanism be to coordinate different AKAPs to interact
with the same signaling partner? In the case of PKA, AKAPs
have varying affinities for the enzyme, which can be affected by
the activation of PKA [43, 113]. For example, Ezrin binds PKA
(RII) only with low affinity [47]. Therefore, it is tempting to
speculate that an AKAP with a higher affinity for PKA can
compete with PKA binding to an AKAP with a lower affinity
for PKA. However, this is thus far unstudied. There have been
limited studies addressing the options of AKAPs affecting each
other, however, it has been published that AKAP5 and
AKAP12 can form heterodimers [31]. The authors showed that
overexpression of AKAP12 in cells that endogenously express
AKAP5, such as HEK293 or A431 cells, potentiates AKAP5-
mediated phosphorylation of ERK1/2 in response to the β2-
agonist isoprenaline. Interestingly, however, AKAP12-
mediated recycling of theβ2-adrenoceptor was unaffected upon
AKAP5 overexpression [31]. We have recently published a
hypothetical model how AKAP5, AKAP12, and Ezrin can
work in harmony to regulate that β2-adrenoceptor expression
at the membrane [80]. However, mechanisms involved in
AKAP dimerization, and how such dimer formation is triggered
by molecular cues still remain obscure. At last, studies referring
to the roles of some AKAPs (e.g., AKAP8) in diseases are very
limited. Nevertheless, further studies are necessary to help us
gain more knowledge about the role of AKAPs in cell cycle
regulation, therefore providing new insights to perhaps develop
AKAP-related therapies to treat diseases caused by abnormal
cell cycle regulation.
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